Benzinga · Oct 19, 2026
Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $180
Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:RGEN) with a Hold and raises the price target from $145 to $180.
RG
NYSE · RGEN
Repligen Corporation
Healthcare · Medical - Instruments & Supplies
$188.64
Down-$11.70 (-6.20%)
Updated Oct 30, 2026, 9:21 PM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.1B
- P/E ratio
- 5,229.48
- Dividend yield
- 0.00%
- 52-week range
- $100.99 – $198.87
- Volume
- 890.27K
- Avg. volume
- 934.31K
Price performance · RGEN
RGEN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
RGEN closed at $188.64 after 21 trading sessions, up 6.44% for the selected period.
- Last close
- $188.64
- Period change
- +6.44%
- Period low
- $163.84
- Period high
- $189.50
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $188.42 | $191.05 | $185.275 | $188.64 | 890.27K |
| Oct 28, 2026 | $173.54 | $185.88 | $173.54 | $184.69 | 1.45M |
| Oct 27, 2026 | $168.34 | $180.00 | $164.88 | $175.80 | 2.11M |
| Oct 26, 2026 | $176.93 | $181.46 | $175.80 | $180.17 | 1.18M |
| Oct 23, 2026 | $178.30 | $179.54 | $174.90 | $176.93 | 1.07M |
| Oct 22, 2026 | $179.45 | $185.025 | $175.96 | $178.71 | 1.27M |
| Oct 21, 2026 | $174.37 | $183.49 | $172.00 | $180.01 | 903.86K |
| Oct 20, 2026 | $176.50 | $180.67 | $174.37 | $178.88 | 877.75K |
| Oct 19, 2026 | $177.82 | $178.66 | $174.2575 | $176.43 | 769.1K |
| Oct 16, 2026 | $183.81 | $186.00 | $172.39 | $175.42 | 1.21M |
| Oct 15, 2026 | $178.28 | $185.99 | $177.4901 | $184.17 | 1.04M |
| Oct 14, 2026 | $175.42 | $181.0667 | $175.39 | $178.20 | 1.22M |
| Oct 13, 2026 | $172.51 | $177.955 | $169.73 | $175.42 | 1.26M |
| Oct 12, 2026 | $171.73 | $173.82 | $169.90 | $172.51 | 899.61K |
| Oct 9, 2026 | $164.21 | $174.82 | $164.21 | $173.88 | 1.34M |
| Oct 8, 2026 | $164.00 | $164.65 | $157.4355 | $163.84 | 1.23M |
| Oct 7, 2026 | $174.75 | $175.04 | $165.99 | $167.22 | 2.63M |
| Oct 6, 2026 | $191.90 | $194.36 | $174.36 | $174.86 | 1.7M |
| Oct 5, 2026 | $178.75 | $191.26 | $178.61 | $189.50 | 1.61M |
| Oct 2, 2026 | $179.32 | $186.52 | $178.00 | $181.70 | 1.46M |
| Oct 1, 2026 | $194.00 | $194.00 | $177.12 | $177.23 | 1.95M |
Latest RGEN news
The latest Smart Investors Daily articles mentioning RGEN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RGEN research
Overview
Company profile and research snapshot.
Company profile
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $171.00
- Implied upside
- —
- Analysts
- 28
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | RBC Capital | Outperform | — |
| Oct 19, 2026 | Canaccord Genuity | Hold | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 9, 2026 | UBS | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 14, 2026
Repligen: A Buy As Its Growth Engine Gears Up
Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. See why RGEN stock is a Buy.
Yahoo · Oct 13, 2026
Repligen to Report Third Quarter 2026 Financial Results
Webcast and Conference Call to Be Held Tuesday, October 27, 2026, at 8:00 a.m. ETWALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended September 30,
Benzinga · Oct 7, 2026
Barclays Maintains Overweight on Repligen, Raises Price Target to $225
Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
